Works by Leyland-Jones, Brian

Results: 46

Predicting Endocrine Responsiveness: Novel Biomarkers on the Horizon.

Published in:

Oncology (08909091), 2009, v. 23, n. 2, p. 154

By:

Kerstann, Kimberly F.;
Bouzyk, Mark;
Abramovit, Mark;
Brian Leyland-Jones

Publication type:

Article

Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor–Positive, Early Breast Cancer.

Published in:

JNCI Cancer Spectrum, 2019, v. 3, n. 4, p. N.PAG, doi. 10.1093/jncics/pkz051

By:

Buechler, Steven A;
Gray, Kathryn P;
Gökmen-Polar, Yesim;
Willis, Scooter;
Thürlimann, Beat;
Kammler, Rosita;
Viale, Giuseppe;
Leyland-Jones, Brian;
Badve, Sunil S;
Regan, Meredith M

Publication type:

Article

Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer.

Published in:

2016

By:

Abramovitz, Mark;
Williams, Casey;
Loibl, Sibylle;
Leyland-Jones, Brian

Publication type:

journal article

Triple Fluorescence staining to Evaluate Mechanism-based Apoptosis following Chemotherapeutic and Targeted Anti-cancer Drugs in Live Tumor Cells.

Published in:

Scientific Reports, 2018, v. 8, n. 1, p. 1, doi. 10.1038/s41598-018-31575-3

By:

De, Pradip;
Carlson, Jennifer H.;
Leyland-Jones, Brian;
Williams, Casey;
Dey, Nandini

Publication type:

Article

A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy.

Published in:

OncoTargets & Therapy, 2015, v. 8, p. 3561, doi. 10.2147/OTT.S90766

By:

Williams, Casey B.;
Mc Mahon, Caitlin;
Ali, Siraj M.;
Abramovitz, Mark;
Williams, Kirstin A.;
Klein, Jessica;
McKean, Heidi;
Yelensky, Roman;
George Jr., Thomas J.;
Elvin, Julia A.;
Soman, Salil;
Lipson, Doron;
Chmielecki, Juliann;
Morosini, Deborah;
Miller, Vincent A.;
Stephens, Philip J.;
Ross, Jeffrey S.;
Leyland-Jones, Brian

Publication type:

Article

Wnt signaling in triple negative breast cancer is associated with metastasis.

Published in:

BMC Cancer, 2013, v. 13, n. 1, p. 1, doi. 10.1186/1471-2407-13-537

By:

Dey, Nandini;
Barwick, Benjamin G.;
Moreno, Carlos S.;
Ordanic-Kodani, Maja;
Zhengjia Chen;
Oprea-Ilies, Gabriella;
Weining Tang;
Catzavelos, Charles;
Kerstann, Kimberly F.;
Sledge Jr., George W.;
Abramovitz, Mark;
Bouzyk, Mark;
De, Pradip;
Leyland-Jones, Brian R.

Publication type:

Article

Wnt signaling in triple negative breast cancer is associated with metastasis.

Published in:

2013

By:

Dey, Nandini;
Barwick, Benjamin G;
Moreno, Carlos S;
Ordanic-Kodani, Maja;
Chen, Zhengjia;
Oprea-Ilies, Gabriella;
Tang, Weining;
Catzavelos, Charles;
Kerstann, Kimberly F;
Sledge Jr, George W;
Abramovitz, Mark;
Bouzyk, Mark;
De, Pradip;
Leyland-Jones, Brian R;
Sledge, George W Jr

Publication type:

journal article

Differential Activation of Wnt-β-Catenin Pathway in Triple Negative Breast Cancer Increases MMP7 in a PTEN Dependent Manner.

Published in:

PLoS ONE, 2013, v. 8, n. 10, p. 1, doi. 10.1371/journal.pone.0077425

By:

Dey, Nandini;
Young, Brandon;
Abramovitz, Mark;
Bouzyk, Mark;
Barwick, Benjamin;
De, Pradip;
Leyland-Jones, Brian

Publication type:

Article

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.

Published in:

2016

By:

Ross, Jeffrey S.;
Gay, Laurie M.;
Wang, Kai;
Ali, Siraj M.;
Chumsri, Saranya;
Elvin, Julia A.;
Bose, Ron;
Vergilio, Jo‐Anne;
Suh, James;
Yelensky, Roman;
Lipson, Doron;
Chmielecki, Juliann;
Waintraub, Stanley;
Leyland‐Jones, Brian;
Miller, Vincent A.;
Stephens, Philip J.

Publication type:

journal article

Dose Scheduling – Herceptin[sup ®].

Published in:

Oncology, 2001, v. 61, p. 31, doi. 10.1159/000055399

By:

Leyland-Jones, Brian

Publication type:

Article

Role of Herceptin[sup ®] in Primary Breast Cancer: Views from North America and Europe.

Published in:

Oncology, 2001, v. 61, p. 83, doi. 10.1159/000055406

By:

Leyland-Jones, Brian;
Smith, Ian

Publication type:

Article

RE: Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies.

Published in:

2015

By:

Rae, James M.;
Leyland-Jones, Brian;
Regan, Meredith;
Thompson, Alastair M.

Publication type:

Letter to the Editor

RE: Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies.

Published in:

2015

By:

Rae, James M;
Leyland-Jones, Brian;
Regan, Meredith;
Thompson, Alastair M

Publication type:

Journal Article

Re: Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA.

Published in:

2014

By:

RAE, JAMES M.;
LEYLAND-JONES, BRIAN;
REGAN, MEREDITH

Publication type:

Letter to the Editor

Response.

Published in:

2014

By:

Rae, James M;
Leyland-Jones, Brian;
Regan, Meredith

Publication type:

Journal Article

Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA.

Published in:

JNCI: Journal of the National Cancer Institute, 2013, v. 105, n. 17, p. 1332, doi. 10.1093/jnci/djt204

By:

Rae, James M.;
Regan, Meredith M.;
Thibert, Jacklyn N.;
Gersch, Christina;
Thomas, Dafydd;
Leyland-Jones, Brian;
Viale, Giuseppe;
Pusztai, Lajos;
Hayes, Daniel E.;
Skaar, Todd;
Van Poznak, Catherine

Publication type:

Article

Erythropoiesis Stimulating Agents: A Personal Journey.

Published in:

2013

By:

Leyland-Jones, Brian

Publication type:

Editorial

Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial.

Published in:

2012

By:

Stanton Jr., Vincent;
Regan, Meredith M.;
Bouzyk, Mark;
Rae, James M.;
Viale, Giuseppe;
Leyland-Jones, Brian;
Hayes, Daniel F.;
Cuzick, Jack;
Sestak, Ivana;
Dowsett, Mitch;
Kelly, Catherine M.;
Pritchard, Kathleen I.

Publication type:

Letter to the Editor

Response.

Published in:

2012

By:

Regan, Meredith M.;
Bouzyk, Mark;
Rae, James M.;
Viale, Giuseppe;
Leyland-Jones, Brian

Publication type:

Letter

CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial.

Published in:

JNCI: Journal of the National Cancer Institute, 2012, v. 104, n. 6, p. 441, doi. 10.1093/jnci/djs125

By:

Regan, Meredith M.;
Leyland-Jones, Brian;
Bouzyk, Mark;
Pagani, Olivia;
Tang, Weining;
Kammler, Roswitha;
Dell’Orto, Patrizia;
Biasi, Maria Olivia;
Thürlimann, Beat;
Lyng, Maria B.;
Ditzel, Henrik J.;
Neven, Patrick;
Debled, Marc;
Maibach, Rudolf;
Price, Karen N.;
Gelber, Richard D.;
Coates, Alan S.;
Goldhirsch, Aron;
Rae, James M.;
Viale, Giuseppe

Publication type:

Article

Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study.

Published in:

Genome Medicine, 2021, v. 13, n. 1, p. 1, doi. 10.1186/s13073-021-00969-w

By:

Sicklick, Jason K.;
Kato, Shumei;
Okamura, Ryosuke;
Patel, Hitendra;
Nikanjam, Mina;
Fanta, Paul T.;
Hahn, Michael E.;
De, Pradip;
Williams, Casey;
Guido, Jessica;
Solomon, Benjamin M.;
McKay, Rana R.;
Krie, Amy;
Boles, Sarah G.;
Ross, Jeffrey S.;
Lee, J. Jack;
Leyland-Jones, Brian;
Lippman, Scott M.;
Kurzrock, Razelle

Publication type:

Article

A systems approach to clinical oncology: Focus on breast cancer.

Published in:

Proteome Science, 2006, v. 4, p. 5, doi. 10.1186/1477-5956-4-5

By:

Abramovitz, Mark;
Leyland-Jones, Brian

Publication type:

Article

Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer.

Published in:

2019

By:

Sun, Yuliang;
Lin, Xiaoqian;
Aske, Jennifer Carlson;
Ye, Ping;
Williams, Casey;
Abramovitz, Mark;
Leyland-Jones, Brian R.

Publication type:

journal article

Bevacizumab confers additional advantage to the combination of trastuzumab plus pertuzumab in trastuzumab‑refractory breast cancer model.

Published in:

2013

By:

Sun, Yuliang;
Dey, Nandini;
Brammer, Melissa;
De, Pradip;
Leyland-Jones, Brian

Publication type:

journal article

Bevacizumab confers additional advantage to the combination of trastuzumab plus pertuzumab in trastuzumab-refractory breast cancer model.

Published in:

Cancer Chemotherapy & Pharmacology, 2013, v. 72, n. 4, p. 733, doi. 10.1007/s00280-013-2233-7

By:

Sun, Yuliang;
Dey, Nandini;
Brammer, Melissa;
De, Pradip;
Leyland-Jones, Brian

Publication type:

Article

Promise of Precision Medicine in Cancers: Lessons Learned.

Published in:

South Dakota Medicine, 2017, v. 70, n. 11, p. 486

By:

Dey, Nandini;
Williams, Casey;
Leyland-Jones, Brian;
De, Pradip

Publication type:

Article

Pharmacology and Pharmacogenetics of Chemotherapeutic Agents.

Published in:

Cancer Investigation, 2009, v. 27, n. 5, p. 482, doi. 10.1080/07357900802574660

By:

Dawood, Shaheenah;
Leyland-Jones, Brian

Publication type:

Article

Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience.

Published in:

Oncologist, 2020, v. 25, n. 11, p. e1803, doi. 10.1002/onco.13532

By:

Bohan, Sandy S.;
Sicklick, Jason K.;
Kato, Shumei;
Okamura, Ryosuke;
Miller, Vincent A.;
Leyland‐Jones, Brian;
Lippman, Scott M.;
Kurzrock, Razelle

Publication type:

Article

A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non‐small cell lung cancer.

Published in:

Cancer Medicine, 2022, v. 11, n. 14, p. 2790, doi. 10.1002/cam4.4635

By:

Solomon, Benjamin;
Callejo, Ana;
Bar, Jair;
Berchem, Guy;
Bazhenova, Lyudmila;
Saintigny, Pierre;
Wunder, Fanny;
Raynaud, Jacques;
Girard, Nicolas;
Lee, J. Jack;
Sulaiman, Raed;
Prouse, Bruce;
Bresson, Catherine;
Ventura, Hila;
Magidi, Shai;
Rubin, Eitan;
Young, Brandon;
Onn, Amir;
Leyland‐Jones, Brian;
Schilsky, Richard L.

Publication type:

Article

Reversal of multidrug resistance to cancer chemotherapy.

Published in:

Cancer (0008543X), 1993, v. 72, n. S11, p. 3484, doi. 10.1002/1097-0142(19931201)72:11+<3484::AID-CNCR2820721615>3.0.CO;2-L

By:

Leyland-Jones, Brian;
Dalton, William;
Fisher, George A.;
Sikic, Branimir I.

Publication type:

Article

Intra- and Interlaboratory Reproducibility of the Sensitivity to Endocrine Therapy Assay for Stage II/III Breast Cancer.

Published in:

Clinical Chemistry, 2021, v. 67, n. 9, p. 1240, doi. 10.1093/clinchem/hvab068

By:

Bossuyt, Veerle;
Lau, Rosanna;
Young, Brandon;
Howe, John Greg;
Zhao, Fengmin;
Leyland-Jones, Brian;
Du, Lili;
Foli, Tiffany;
Hatzis, Christos;
Fraser Symmans, W.

Publication type:

Article

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.

Published in:

Breast Cancer Research & Treatment, 2015, v. 154, n. 3, p. 543, doi. 10.1007/s10549-015-3634-6

By:

Leyland-Jones, Brian;
Gray, Kathryn;
Abramovitz, Mark;
Bouzyk, Mark;
Young, Brandon;
Long, Bradley;
Kammler, Roswitha;
Dell'Orto, Patrizia;
Biasi, Maria;
Thürlimann, Beat;
Harvey, Vernon;
Neven, Patrick;
Arnould, Laurent;
Maibach, Rudolf;
Price, Karen;
Coates, Alan;
Goldhirsch, Aron;
Gelber, Richard;
Pagani, Olivia;
Viale, Giuseppe

Publication type:

Article

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.

Published in:

Breast Cancer Research & Treatment, 2015, v. 151, n. 2, p. 373, doi. 10.1007/s10549-015-3378-3

By:

Leyland-Jones, Brian;
Gray, Kathryn;
Abramovitz, Mark;
Bouzyk, Mark;
Young, Brandon;
Long, Bradley;
Kammler, Roswitha;
Dell'Orto, Patrizia;
Biasi, Maria;
Thürlimann, Beat;
Lyng, Maria;
Ditzel, Henrik;
Harvey, Vernon;
Neven, Patrick;
Treilleux, Isabelle;
Rasmussen, Birgitte;
Maibach, Rudolf;
Price, Karen;
Coates, Alan;
Goldhirsch, Aron

Publication type:

Article

Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.

Published in:

Breast Cancer Research & Treatment, 2009, v. 113, n. 2, p. 357, doi. 10.1007/s10549-008-9926-3

By:

Lund, Mary;
Trivers, Katrina;
Porter, Peggy;
Coates, Ralph;
Leyland-Jones, Brian;
Brawley, Otis;
Flagg, Elaine;
O’Regan, Ruth;
Gabram, Sheryl;
Eley, J.

Publication type:

Article

Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis.

Published in:

PLoS ONE, 2016, v. 11, n. 2, p. 1, doi. 10.1371/journal.pone.0149183

By:

Willis, Scooter;
Villalobos, Victor M.;
Gevaert, Olivier;
Abramovitz, Mark;
Williams, Casey;
Sikic, Branimir I.;
Leyland-Jones, Brian

Publication type:

Article

Autologous Bone Marrow Transplantation.

Published in:

Annals of Internal Medicine, 1989, v. 110, n. 1, p. 51, doi. 10.7326/0003-4819-110-1-51

By:

Cheson, Bruce D.;
Lacerna, Leocadio;
Leyland-Jones, Brian;
Sarosy, Gisele;
Wittes, Robert E.

Publication type:

Article

2-Deoxycoformycin (Pentostatin) for Lymphoid Malignancies.

Published in:

Annals of Internal Medicine, 1988, v. 108, n. 5, p. 733, doi. 10.7326/0003-4819-108-5-733

By:

O'Dwyer, Peter J.;
Wagner, Barbara;
Leyland-Jones, Brian;
Wittes, Robert E.;
Cheson, Bruce D.;
Hoth, Daniel F.

Publication type:

Article

Down's Syndrome and Triple Negative Breast Cancer: A Rare Occurrence of Distinctive Clinical Relationship.

Published in:

2017

By:

Dey, Nandini;
Krie, Amy;
Klein, Jessica;
Williams, Kirstin;
McMillan, Amanda;
Elsey, Rachel;
Sun, Yuliang;
Williams, Casey;
De, Pradip;
Leyland-Jones, Brian

Publication type:

Case Study

BOOK REVIEWS.

Published in:

JNCI: Journal of the National Cancer Institute, 1990, v. 82, n. 7, p. 622

By:

LEYLAND-JONES, BRIAN

Publication type:

Article

BOOK REVIEWS.

Published in:

JNCI: Journal of the National Cancer Institute, 1989, v. 81, n. 17, p. 1328, doi. 10.1093/jnci/81.17.1328

By:

LEYLAND-JONES, BRIAN

Publication type:

Article

4-Ipomeanol: A Novel Investigational New Drug for Lung Cancer.

Published in:

JNCI: Journal of the National Cancer Institute, 1989, v. 81, n. 15, p. 1133

By:

Christian, Michaele C.;
Wittes, Robert E.;
Leyland-Jones, Brian;
McLemore, Theodore L.;
Smith, Adaline C.;
Grieshaber, Charles K.;
Chabner, Bruce A.;
Boyd, Michael R.

Publication type:

Article

Pentostatin in Hairy Cell Leukemia: Treatment by the Special Exception Mechanism.

Published in:

JNCI: Journal of the National Cancer Institute, 1989, v. 81, n. 6, p. 448

By:

Grem, Jean L.;
King, Susan A.;
Cheson, Bruce D.;
Leyland-Jones, Brian;
Wittes, Robert E.

Publication type:

Article

Whither the Modulation of Platinum?

Published in:

JNCI: Journal of the National Cancer Institute, 1988, v. 80, n. 18, p. 1432

By:

Leyland-Jones, Brian

Publication type:

Article

Cephalotaxine Esters: Antileukemic Advance or Therapeutic Failure?

Published in:

JNCI: Journal of the National Cancer Institute, 1988, v. 80, n. 14, p. 1095

By:

Grem, Jean L.;
Cheson, Bruce D.;
King, Susan A.;
Leyland-Jones, Brian;
Suffness, Matthew

Publication type:

Article

The Role of Methotrexate in Osteosarcoma.

Published in:

JNCI: Journal of the National Cancer Institute, 1988, v. 80, n. 9, p. 626

By:

Grem, Jean L.;
King, Susan A.;
Wittes, Robert E.;
Leyland-Jones, Brian

Publication type:

Article

Tamoxifen metabolic patterns within a glioma patient population treated with high-dose tamoxifen.

Published in:

British Journal of Clinical Pharmacology, 1997, v. 43, n. 2, p. 189, doi. 10.1046/j.1365-2125.1997.05029.x

By:

Ducharme, Julie;
Fried, Karen;
Shenouda, George;
Leyland-Jones, Brian;
Wainer, Irving W.

Publication type:

Article